BIIB Jan 2025 165.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:00PM EDT. Market open.
| Previous close | 130.30 |
| Open | 130.00 |
| Bid | 159.00 |
| Ask | 169.00 |
| Strike | 165.00 |
| Expiry date | 2025-01-17 |
| Day's range | 130.00 - 130.30 |
| Contract range | N/A |
| Volume | |
| Open interest | 11 |
ZacksWhat's in Store for Biogen (BIIB) This Earnings Season?
Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been moderate.
ZacksGear Up for Biogen (BIIB) Q1 Earnings: Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Biogen (BIIB), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Investor's Business DailyIs Eli Lilly Stock A Buy After Weight-Loss Drug Succeeds In Sleep Apnea Patients?
Lilly is soon planning to ask global regulators to approve tirzepatide for sleep apnea treatment. Is Eli Lilly stock a buy?
© 2024 Yahoo. All rights reserved.